JPMorgan Chase & Co. Acquires 31,352 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

JPMorgan Chase & Co. grew its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 85.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,148 shares of the company's stock after acquiring an additional 31,352 shares during the period. JPMorgan Chase & Co. owned 0.10% of Nurix Therapeutics worth $1,531,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in NRIX. Wellington Management Group LLP boosted its holdings in Nurix Therapeutics by 8.8% in the 3rd quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company's stock valued at $78,243,000 after purchasing an additional 280,240 shares during the period. Geode Capital Management LLC boosted its stake in shares of Nurix Therapeutics by 9.6% in the third quarter. Geode Capital Management LLC now owns 1,448,040 shares of the company's stock valued at $32,544,000 after buying an additional 126,306 shares during the period. Driehaus Capital Management LLC acquired a new stake in Nurix Therapeutics during the second quarter worth approximately $26,778,000. Millennium Management LLC lifted its position in shares of Nurix Therapeutics by 60.2% during the 2nd quarter. Millennium Management LLC now owns 599,623 shares of the company's stock valued at $12,514,000 after acquiring an additional 225,374 shares during the period. Finally, FMR LLC grew its stake in Nurix Therapeutics by 675.9% during the third quarter. FMR LLC now owns 586,902 shares of the company's stock worth $13,188,000 after buying an additional 511,256 shares in the last quarter.

Nurix Therapeutics Stock Performance

Shares of Nurix Therapeutics stock traded down $0.03 on Friday, hitting $19.93. The company had a trading volume of 522,622 shares, compared to its average volume of 676,975. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -6.85 and a beta of 2.14. Nurix Therapeutics, Inc. has a 1 year low of $7.65 and a 1 year high of $29.56. The stock has a 50 day moving average of $20.36 and a 200-day moving average of $22.45.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Stephens reiterated an "overweight" rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research report on Tuesday. Royal Bank of Canada dropped their price objective on shares of Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating for the company in a research note on Monday, October 14th. HC Wainwright upped their price target on shares of Nurix Therapeutics from $30.00 to $35.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Jefferies Financial Group started coverage on Nurix Therapeutics in a report on Friday, October 11th. They set a "buy" rating and a $41.00 price objective on the stock. Finally, BMO Capital Markets initiated coverage on Nurix Therapeutics in a report on Friday, December 6th. They issued an "outperform" rating and a $35.00 target price for the company. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, Nurix Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $30.35.

Insider Activity at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,437 shares of Nurix Therapeutics stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total transaction of $83,519.10. Following the completion of the sale, the insider now directly owns 50,670 shares of the company's stock, valued at approximately $1,231,281. The trade was a 6.35 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Houte Hans Van sold 2,368 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total transaction of $57,542.40. Following the transaction, the chief financial officer now owns 37,270 shares in the company, valued at $905,661. The trade was a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,351 shares of company stock worth $227,158. Company insiders own 7.20% of the company's stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.